Cowen & Co Downgrades GTx, Inc (GTXI) to Underperform
More News related to GTXI
- GTx Announces Corporate Presentation at Lazard Capital Markets Annual Healthcare Conference
- GTx (GTXI) Posts Q3 Loss of 35c, In-Line with Estimates
- GTx, Inc. Reports Third Quarter 2009 Corporate Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- GTx, Inc. Announces Third Quarter 2009 Corporate Results Conference Call and Webcast
More News related to Downgrades
- RBC Capital Downgrades Church & Dwight (CHD) from Top Pick to Outperform
- JMP Securities Downgrades NuVasive (NUVA) to Market Perform
- Brean Murray Downgrades NuVasive (NUVA) to Hold; Reimbursement Issues Struck a Nerve
- Merriman Curhan Ford Downgrades Netflix (NFLX) to Neutral; Risk Lies More With Initial 1Q Guidance
- Shields & Co. Downgrades ALLETE, Inc. (ALE) to Hold
Cowen & Co downgrades GTx, Inc (Nasdaq: GTXI) from Neutral to Underperform.
To see more analyst ratings on GTXI Click Here.
GTx, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other medical conditions.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
